ArticleIranian journal of basic medical sciences2012
Cannabinoid CB1 Receptors Mediate the Gastroprotective Effect of Neurotensin.
Article in Iranian journal of basic medical sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 26 citations in OpenAlex.
- The endocannabinoid system and NGF are involved in the mechanism of action of resveratrol: a multi-target nutraceutical with therapeutic potential in neuropsychiatric disorders.Psychopharmacology · 2016Article
- CB1 cannabinoid receptors are involved in neuroleptic-induced enhancement of brain neurotensin.Iranian journal of basic medical sciences · 2014Article
- Implication of NGF and endocannabinoid signaling in the mechanism of action of sesamol: a multi-target natural compound with therapeutic potential.Psychopharmacology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSeveral lines of evidence indicate that neuropeptides exhibit protective properties against gastroduodenal ulcers. Neurotensin, a gut-brain neuropeptide, is implicated in a number of physiological processes in the central nervous system and peripheral tissues including gastrointestinal tract. In the present study, we aimed to investigate the gastroprotective potential of either peripherally or centrally administered neurotensin with a look at the role of the cannabinoid CB1 receptors which are located in brain areas implicated in the regulation of gastric functions. MATERIALS AND
methodsGastric mucosal damage was induced by intragastric administration of acidified ethanol in male Wistar rats. One hour later, gastric lesions were evaluated macroscopically. In gastroprotection study, neurotensin was administered either intravenously (1.5, 3, and 5 µM/kg) or intracerebroventricularly (0.5, 1, and 2.5 nM/rat) 30 min before the ethanol challenge. In order to evaluate the involvement of central CB1 receptors in the gastroprotective effect of neurotensin, the CB1 receptor antagonist AM251 (5, 10, and 15 nM/rat) was given i.c.v. 30 min prior to the administration of neurotensin. The effects of AM251 on the intact stomach and ethanol-induced gastric lesions were also evaluated.
resultsAcidified ethanol induced large areas of gastric lesions which were significantly reduced by the highest dose of neurotensin in i.v. or i.c.v. application. The gastroprotective effect of neurotensin was prevented by pretreatment with 15 nM/rat AM251. AM251 had no effect by itself.
conclusionPeripherally or centrally given neurotensin protects gastric mucosa against damage induced by acidified ethanol through the activation of central cannabinoid CB1 receptors.
Indexed as
Identifiers
23492756PMC3586888W2186378681What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.